Skip to main content
Erschienen in: European Radiology 3/2009

01.03.2009 | Urogenital

Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging

verfasst von: Stefano Cirillo, Massimo Petracchini, Lorenza Scotti, Teresa Gallo, Annalisa Macera, Maria Cristina Bona, Cinzia Ortega, Pietro Gabriele, Daniele Regge

Erschienen in: European Radiology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

To evaluate diagnostic performance of endorectal magnetic resonance (eMR) for diagnosing local recurrence of prostate cancer (PC) in patients with previous radical prostatectomy (RP) and to assess whether contrast-enhanced (CE)-eMR improved diagnostic accuracy in comparison to unenhanced study. Unenhanced eMR data of 72 male patients (mean of total PSA: 1.23 ± 1.3 ng/ml) with previous RP were interpreted retrospectively and classified either as normal or suspicious for local recurrence. All eMR examinations were re-evaluated also on CE-eMR 4 months after the first reading. Images were acquired on a 1.5-T system. These data were compared to the standard of reference for local recurrence: prostatectomy bed biopsy results; choline positron emission tomography results; PSA reduction or increase after pelvic radiotherapy; PSA modification during active surveillance. Sensitivity, specificity, predictive positive value, negative predictive value and accuracy were 61.4%, 82.1%, 84.4%, 57.5% and 69.4% for unenhanced eMR and 84.1%, 89.3%, 92.5%, 78.1% and 86.1% for CE-eMR. A statistically significant difference was found between accuracy and sensitivity of the two evaluations (χ2 = 5.33; p = 0.02 and χ2 = 9.00; p = 0.0027). EMR had great accuracy for visualizing local recurrence of PC after RP. CE-eMR improved diagnostic performance in comparison with T2-weighted imaging alone.
Literatur
2.
3.
Zurück zum Zitat Shibata A, Whittemore AS (1998) Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer I 93:1109–1110CrossRef Shibata A, Whittemore AS (1998) Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer I 93:1109–1110CrossRef
4.
Zurück zum Zitat Lu-Yao GL, Greenberg ER (1994) Change in prostate cancer incidence and treatment in USA. Lancet 343:251–254CrossRefPubMed Lu-Yao GL, Greenberg ER (1994) Change in prostate cancer incidence and treatment in USA. Lancet 343:251–254CrossRefPubMed
5.
Zurück zum Zitat Lu-Yao GL, Yao S (1997) Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 349:906–910CrossRefPubMed Lu-Yao GL, Yao S (1997) Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 349:906–910CrossRefPubMed
6.
Zurück zum Zitat Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–23CrossRefPubMed Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–23CrossRefPubMed
7.
Zurück zum Zitat Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164:101–105CrossRefPubMed Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164:101–105CrossRefPubMed
8.
Zurück zum Zitat Catalona WJ, Smith DS (1994) 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837–1842PubMed Catalona WJ, Smith DS (1994) 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837–1842PubMed
9.
Zurück zum Zitat Freedland SJ, Mangold LA, Walsh PC, Partin AW (2005) The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol 174:1276–1281CrossRefPubMed Freedland SJ, Mangold LA, Walsh PC, Partin AW (2005) The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol 174:1276–1281CrossRefPubMed
10.
Zurück zum Zitat Kattan MW, Wheeler TM, Scardino PT (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17:1499–1507PubMed Kattan MW, Wheeler TM, Scardino PT (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17:1499–1507PubMed
11.
Zurück zum Zitat Trapasso JG, deKernion JB, Smith RB, Dorey F (1994) The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821–1825PubMed Trapasso JG, deKernion JB, Smith RB, Dorey F (1994) The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821–1825PubMed
12.
Zurück zum Zitat Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM (1994) Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152 5 Pt 2):1850–1857 Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM (1994) Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152 5 Pt 2):1850–1857
13.
Zurück zum Zitat Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen. a decade of discovery – what we have learned and where we are going. J Urol 162:293–300CrossRefPubMed Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen. a decade of discovery – what we have learned and where we are going. J Urol 162:293–300CrossRefPubMed
14.
Zurück zum Zitat Freedland SJ, Sutter ME, Dorey F, Aronson WJ (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61:365–369CrossRefPubMed Freedland SJ, Sutter ME, Dorey F, Aronson WJ (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61:365–369CrossRefPubMed
15.
Zurück zum Zitat Laufer M, Pound CR, Carducci MA, Eisenberger MA (2000) Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 55:309–315CrossRefPubMed Laufer M, Pound CR, Carducci MA, Eisenberger MA (2000) Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 55:309–315CrossRefPubMed
16.
Zurück zum Zitat Amling CL, Bergstralh EJ, Blute ML, Slezak A, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cutpoint? J Urol 165:1146–1151CrossRefPubMed Amling CL, Bergstralh EJ, Blute ML, Slezak A, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cutpoint? J Urol 165:1146–1151CrossRefPubMed
17.
Zurück zum Zitat Scattoni V, Montorsi F, Picchio M et al (2004) Diagnosis of local recurrence after radical prostatectomy. BJU Int 93:680–688CrossRefPubMed Scattoni V, Montorsi F, Picchio M et al (2004) Diagnosis of local recurrence after radical prostatectomy. BJU Int 93:680–688CrossRefPubMed
18.
Zurück zum Zitat Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385CrossRefPubMed Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385CrossRefPubMed
19.
Zurück zum Zitat Kane CJ, Amling CL, Johnstone PA et al (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61:607–611CrossRefPubMed Kane CJ, Amling CL, Johnstone PA et al (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61:607–611CrossRefPubMed
20.
Zurück zum Zitat Cher ML, Bianco FJ Jr, Lam JS et al (1998) Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160:1387–1391CrossRefPubMed Cher ML, Bianco FJ Jr, Lam JS et al (1998) Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160:1387–1391CrossRefPubMed
21.
Zurück zum Zitat Seltzer MA, Barbaric Z, Belldegrun A et al (1999) Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162:1322–1328CrossRefPubMed Seltzer MA, Barbaric Z, Belldegrun A et al (1999) Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162:1322–1328CrossRefPubMed
22.
Zurück zum Zitat Oyen RH, van Poppel HP, Ameye FE et al (1994) Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 190:315–322PubMed Oyen RH, van Poppel HP, Ameye FE et al (1994) Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 190:315–322PubMed
23.
Zurück zum Zitat Lecouvet FE, Geukens D, Stainier A et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281–3287CrossRefPubMed Lecouvet FE, Geukens D, Stainier A et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281–3287CrossRefPubMed
24.
Zurück zum Zitat Walsh JW, Amendola MA, Konerding KF, Tisnado J, Hazra TA (1980) Computed tomographic detection of pelvic and inguinal lymph-node metastases from primary and recurrent pelvic malignant disease. Radiology 137:157–166PubMed Walsh JW, Amendola MA, Konerding KF, Tisnado J, Hazra TA (1980) Computed tomographic detection of pelvic and inguinal lymph-node metastases from primary and recurrent pelvic malignant disease. Radiology 137:157–166PubMed
25.
Zurück zum Zitat Cimitan M, Bortolus R, Morassut S et al (2006) 18F-Fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33:1387–1398CrossRefPubMed Cimitan M, Bortolus R, Morassut S et al (2006) 18F-Fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33:1387–1398CrossRefPubMed
26.
Zurück zum Zitat Reske SN, Blumstein NM, Glatting G (2008) 11C-Choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35:9–17CrossRefPubMed Reske SN, Blumstein NM, Glatting G (2008) 11C-Choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35:9–17CrossRefPubMed
27.
Zurück zum Zitat De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) 11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32–38CrossRefPubMed De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) 11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32–38CrossRefPubMed
28.
Zurück zum Zitat Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T (2005) 11C-Choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74:214–220CrossRefPubMed Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T (2005) 11C-Choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74:214–220CrossRefPubMed
29.
Zurück zum Zitat Silverman JM, Krebs TL (1997) MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. Am J Roentgenol 168:379–385 Silverman JM, Krebs TL (1997) MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. Am J Roentgenol 168:379–385
30.
Zurück zum Zitat Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF (1999) Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17:1155PubMed Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF (1999) Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17:1155PubMed
31.
Zurück zum Zitat Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy. Correlation of US features with prostatic fossa biopsy findings. Radiology 219:432–439PubMed Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy. Correlation of US features with prostatic fossa biopsy findings. Radiology 219:432–439PubMed
32.
Zurück zum Zitat Goldenberg SL, Carter M, Dashefsky S, Cooperberg PL (1992) Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient. J Urol 147:1307–1309PubMed Goldenberg SL, Carter M, Dashefsky S, Cooperberg PL (1992) Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient. J Urol 147:1307–1309PubMed
33.
Zurück zum Zitat Parra RO, Wolf RM, Huben RP (1990) The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrences after a radical urological pelvic operation. J Urol 144:707–709PubMed Parra RO, Wolf RM, Huben RP (1990) The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrences after a radical urological pelvic operation. J Urol 144:707–709PubMed
34.
Zurück zum Zitat Abi-Aad AS, Macfarlane MT, Stein A, deKernion JB (1992) Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 147:952–955PubMed Abi-Aad AS, Macfarlane MT, Stein A, deKernion JB (1992) Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 147:952–955PubMed
35.
Zurück zum Zitat Kapoor DA, Wasserman NF, Zhang G, Reddy PK (1993) Value of transrectal ultrasound in identifying local disease after radical prostatectomy. Urology 41:594–597CrossRefPubMed Kapoor DA, Wasserman NF, Zhang G, Reddy PK (1993) Value of transrectal ultrasound in identifying local disease after radical prostatectomy. Urology 41:594–597CrossRefPubMed
36.
Zurück zum Zitat Foster LS, Jajodia P, Fournier G Jr, Shinohara K, Carroll P, Narayan P (1993) The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 149:1024–1028PubMed Foster LS, Jajodia P, Fournier G Jr, Shinohara K, Carroll P, Narayan P (1993) The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 149:1024–1028PubMed
37.
Zurück zum Zitat Kramer S, Gorich J, Gottfried HW et al (1997) Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 70:995–999PubMed Kramer S, Gorich J, Gottfried HW et al (1997) Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 70:995–999PubMed
38.
Zurück zum Zitat Kotzerke J, Volkmer BG, Glatting G et al (2003) Intraindividual comparison of 11C-acetate and 11C-choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42:25–30PubMed Kotzerke J, Volkmer BG, Glatting G et al (2003) Intraindividual comparison of 11C-acetate and 11C-choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42:25–30PubMed
39.
Zurück zum Zitat Heinisch M, Dirisamer A, Loidl W et al (2006) Positron emission tomography/computed tomography with F18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imaging Biol 8:43–48CrossRefPubMed Heinisch M, Dirisamer A, Loidl W et al (2006) Positron emission tomography/computed tomography with F18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imaging Biol 8:43–48CrossRefPubMed
40.
Zurück zum Zitat Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN (2002) C11-Acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29:1380–1384CrossRefPubMed Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN (2002) C11-Acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29:1380–1384CrossRefPubMed
41.
Zurück zum Zitat Vees H, Buchegger F, Albrecht S (2007) 18F-Choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int 99:1415–1420CrossRefPubMed Vees H, Buchegger F, Albrecht S (2007) 18F-Choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int 99:1415–1420CrossRefPubMed
42.
Zurück zum Zitat Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE (2007) Evaluation of 11C-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100:786–793CrossRefPubMed Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE (2007) Evaluation of 11C-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100:786–793CrossRefPubMed
Metadaten
Titel
Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging
verfasst von
Stefano Cirillo
Massimo Petracchini
Lorenza Scotti
Teresa Gallo
Annalisa Macera
Maria Cristina Bona
Cinzia Ortega
Pietro Gabriele
Daniele Regge
Publikationsdatum
01.03.2009
Verlag
Springer-Verlag
Erschienen in
European Radiology / Ausgabe 3/2009
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-008-1174-8

Weitere Artikel der Ausgabe 3/2009

European Radiology 3/2009 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.